Featured articles from the journal CHEST®, November 2022

The November issue of CHEST contains 51 articles, including clinically relevant research, reviews, case series, commentary and more. Each month, the journal also offers complementary web and multimedia activities, including visual abstracts, to expand the reach of its most interesting, timely and relevant research.

“Included in the November issue of the journal CHEST is the latest guideline on Perioperative Management of Antithrombotic Therapy,” says Editor-in-Chief, Peter Mazzone, MD, MPH, FCCP. “An update to the 2012 edition, the new guideline addresses 43 Patients-Interventions-Comparators-Outcomes questions related to the perioperative management of patients who are receiving long-term oral anticoagulant or antiplatelet therapy and require an elective surgery or procedure.”

Also included in the current issue of CHEST:

• Chest Infections

  In original research, “Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19,” results did not support the use of convalescent plasma as a treatment for adults hospitalized with COVID-19. A visual abstract for the research can be viewed here and an animation of the research can be viewed here.

• COPD

“Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy” finds that single-inhaler triple therapy was associated with significant reductions in health care resource use, with consequent cost savings. A visual abstract for the research can be viewed here.

• Education and Clinical Practice

Associated with Long COVID, “Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome” finds that pyridostigmine improves aerobic capacity in ME/CFS.

• Sleep

Looking at short-term changes, “Air Pollution and the Effectiveness of Positive Airway Pressure Therapy in Individuals with Sleep Apnea” demonstrated that air pollution, even at the relatively low levels, showed a measurable association with a change in objective PAP treatment effectiveness. A visual abstract for the research can be viewed here.

---

Notes for editors

To view the entire November issue of CHEST journal (volume 162, issue 5), published by Elsevier, visit journal.chestnet.org and follow @journal_CHEST on Twitter for the latest journal news.

Full text of these articles and interviews with the authors are available to credentialed journalists upon request; contact Laura DiMasi, PR and Communications Specialist, American College of Chest Physicians (CHEST), at [email protected].

About the journal CHEST^®

The journal CHEST, the official publication of the American College of Chest Physicians®, features the best in peer-reviewed, cutting-edge original research in the multidisciplinary specialties of chest medicine: pulmonary, critical care, and sleep medicine; thoracic surgery; cardiorespiratory interactions; and related disciplines. Published since 1935, it is home to the highly regarded clinical practice guidelines and consensus statements. Access the journal CHEST online at journal.chestnet.org.

About the American College of Chest Physicians

The American College of Chest Physicians^® (CHEST) is the global leader in the prevention, diagnosis, and treatment of chest diseases. Its mission is to champion advanced clinical practice, education, communication, and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For information about the American College of Chest Physicians, and its flagship journal CHEST^®, visit chestnet.org.

About Elsevier

Elsevier is a global leader in advanced information and decision support. For over a century, we have been helping advance science and healthcare to advance human progress. We support academic and corporate research communities, doctors, nurses, future healthcare professionals and educators across 170 countries in their vital work. We do this by delivering mission-critical insights and innovative solutions that combine trusted, evidence-based scientific and medical content with cutting-edge AI technologies to help impact makers achieve better outcomes. We champion inclusion and sustainability by embedding these values into our products and culture, working with the communities that we serve. The Elsevier Foundation supports research and health partnerships around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information, visit www.elsevier.com and follow us on social media @ElsevierConnect.